Last updated 2026-07-26
- Acquired by Qualigen Diagnostics, May 2022
- Raised $40k grant, May 2025
- Raised $500k Series A, Dec 2024
Total raised
$4.5M
Last: Grant 2025-06
Stage
Seed
Founded
2017
Headcount
7
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
Nanosynex is a MedTech company developing a rapid diagnostic test for bacterial infections and antimicrobial susceptibility testing (AST). The company's technology, based on microfluidics, aims to provide faster and more accurate results than traditional methods, helping doctors prescribe targeted antibiotics and combat antibiotic resistance. Nanosynex's solution includes a disposable test platform, hardware, and analysis software. The company's core technology originated from research by Professor Shulamit Levenberg at the Technion – Israel Institute of Technology.
Funding history · 6 rounds · $4.5M total
2025-05
Grant
$40K
2024-12
A Round
$500K
2019-05
Grant
$2.5M
2018-11
Seed
$1.0M
2018-10
Grant
$500K
2018-07
Pre-Seed
Undisclosed
Headcount over time
From 6 (2018-08) to 7 (2026-01) · +1 (+17%) · 15 points · source: Finder history + radar grounding
Q&A
- What is Nanosynex's primary focus?
- Nanosynex is focused on developing and commercializing an innovative antimicrobial susceptibility test (AST) that uses a microfluidic disposable test cartridge platform.
- When was Nanosynex founded?
- Nanosynex was founded in February 2017.
- What is the total amount of funding Nanosynex has raised to date?
- Nanosynex has raised a total of $6,340,000 USD.
- Which organizations provided grant funding to Nanosynex in June 2025?
- In June 2025, Nanosynex received grant funding from Synergy7 and Israel Innovation Authority.
- How many employees does Nanosynex currently have?
- Nanosynex currently has 1-10 employees.
- Who are the co-founders of Nanosynex?
- The co-founders of Nanosynex are Diane Abensur, who serves as CEO, and Michelle Heymann, who is VP Marketing & Operations.
- What is the origin of Nanosynex's technology?
- Nanosynex's technology stems from research discoveries made in the lab of Professor Shulamit Levenberg, dean of the Faculty of Biomedical Engineering at the Technion.
- What is Nanosynex's primary sector?
- Nanosynex's primary sector is Health Tech & Life Sciences.
Team · 2
Diane Abensur
Founder · Co-Founder & CEO
Michelle Heymann
Founder · Co-Founder, VP Marketing & Operations
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical Decision Support
Technologies
BiologicalsPlatforms & InterfacesSoftware
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProviders
Business model
B2B
Highlights
1 PatentsVerified
Tags
personalized-medicinenon-invasivedetectionnanotechnologylaboratoriesclinicsinfectious-diseasediagnosticshospitalsblood-testmedical-technologiesbacteriahealthcare-providersurologyhardwaresoftware-platformschoolsbiotechnologyairports
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nanosynex.com/ |
|---|---|
| linkedin.com/company/22294309 | |
| facebook.com/nanosynex |
Identifiers & details
| Founded | 2017-2 |
|---|---|
| Employees (exact) | 7 |
| Offices | Ness Ziona |
Acquisitions & public offerings
Acquired by Qualigen Diagnostics 2022-05
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | nanosynex.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515609220 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2017-02-09 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2023 |
| Active charges / liens | 0 |
| Registry events | 2 — charge (1), violation (1) |
| Registered address | בן יהודה 178 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2025-11-25 | סילוק שעבוד |
| 2026-06-25 | עדכון הפרה |